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A double-blind, randomized, placebo-controlled trial was conducted to evaluate the
efficacy and safety of fleroxacin for one or two days as treatment for patients with
travellers' diarrhoea. A total of 195 patients who were suffering with acute diarrhoea
of less than six days' duration were enrolled. One hundred and fifty-one patients, of
whom 49 received placebo, 54 received fleroxacin 400 mg for one day and 48 received
fleroxacin 400 mg for two days, were included in the analysis of efficacy. The results
showed that fleroxacin was significantly superior to placebo, but that there was no
significant difference in terms of efficacy between the one- and two-day regimens.
Adverse events, particularly minor neuropsychiatric disturbances such as headache
and insomnia, were significantly more common amongst patients receiving active
treatment. In conclusion, a single dose of fleroxacin 400 mg could be recommended
as self-treatment for visitors to high-risk countries who develop travellers' diarrhoea.
Introduction
Travellers' diarrhoea affects 30-50% of visitors from industrialized to developing
countries (Steffen et al., 1983). It is usually mild, self-limiting and of approximately four
days' duration, although symptoms may be prolonged for more than seven days in
about 10% of cases (Gorbach, 1982; Steffen et al, 1983). Many of the aetiological agents
of travellers' diarrhoea have been identified; the most frequently implicated pathogens
are strains of enterotoxigenic Escherichia coli (ETEC), which have been isolated from
40-60% of those patients with travellers' diarrhoea who have positive stool cultures
(Sack, 1990).
Both prophylactic and therapeutic approaches to travellers' diarrhoea have been
investigated. Treatment strategies have included fluid replacement, bismuth subsalicy-
late for symptomatic relief, antimotility drugs such as loperamide, and antimicrobial
agents. Considerable controversy surrounds the administration of antibiotics to
patients with travellers' diarrhoea. The principal arguments against their use have been
the risk of emergence of resistance to the agent prescribed (Farrar, 1985; Murray et al.,
1985) and side-effects, particularly allergic reactions. In both 1985 and 1992 it was
recommended that antibiotic therapy should be reserved for severe, prolonged or
dysenteric illnesses and that mild or moderate diarrhoea could be treated with drugs
other than antibiotics, such as loperamide or bismuth subsalicylate (National Institute
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of Health Concensus Development Conference, 1985; Farthing et al, 1992). On the
other hand, antimicrobial therapy has been shown to reduce the duration of symptoms
to between 24 and 36 h (Ericsson et al, 1987) and, when combined with loperamide, to
an even shorter period (Ericsson et al, 1990).
Several antibiotics, including co-trimoxazole, doxycycline and mecillinam, have been
considered for the treatment of patients with travellers' diarrhoea (Steffen et al, 1988).
However, bacterial resistance to each of these agents has been demonstrated in various
parts of the world (Farrar, 1985) and alternatives are, therefore, necessary. In clinical
trials where they have been evaluated as either treatment or prophylaxis, ciprofloxacin
and norfloxacin have been shown to be effective (Johnson et al, 1986; DuPont, Corrado
& Sabbaj, 1987; Ericsson et al, 1987; Lolekha et al, 1988; Scott et al, 1990). Fleroxacin
is a new 6,8-difluoro-4-quinolone which also exhibits a broad spectrum of antibacterial
activity (Hohl, von Graevenitz & Zollinger-Iten, 1988). It is rapidly absorbed after oral
administration, reaches maximum serum concentrations within 1-2 h and has a long
elimination half-life (8-12 h) which allows once-daily dosing. Fleroxacin also appears to
be more active than norfloxacin in experimental infections (Hof & Fabrig, 1988). This
study was undertaken to compare the efficacy and safety of fleroxacin 400 mg, adminis-
tered orally once daily for either one or two days, with placebo as treatment for patients
with travellers' diarrhoea.
Patients and methods
Hotel guests at a resort in The Gambia who were suffering with travellers' diarrhoea
were enrolled in this double-blind, randomized, placebo-controlled study after giving
written consent. The subjects were of either sex, between 18 and 80 years of age and
suffering with an acute diarrhoeal illness of less than six days' duration; diarrhoea was
defined as the passage of at least one watery or soft (unformed) stool, accompanied by
abdominal cramps, vomiting or nausea. Exclusion criteria were: pregnancy; lactation; a
female of child-bearing potential in whom pregnancy could not be excluded; a known
or suspected allergy to nalidixic acid or its derivatives; hepatic disease; a history of
convulsions; severe concomitant disease; previous participation in clinical trials
involving fleroxacin or antimicrobial agents administered in the seven days preceding
entry to the study. Other medications, with the exception of malaria prophylaxis, oral
contraceptives, antihypertensive agents, hypnotics, oestrogens or vitamin supplements,
were not permitted during the trial.
The clinical signs and symptoms of those patients fulfilling the entry criteria were
recorded and a stool sample was submitted. Each subject was then randomly assigned
to receive fleroxacin 400 mg od for two days (fleroxacin-2 group), fleroxacin 400 mg on
day one and the placebo on day two (fleroxacin-1 group) or a placebo od for two days.
The doses were administered by a physician who subsequently interviewed the patients
at 24, 48 and 72 h. Throughout the 72 h of the study, patients recorded in a diary every
12 h the consistency of their stools and other symptoms.
Baseline stool samples underwent microbiological examination in Houston, Texas
within 11 days according to the methods of Morgan et al (1984). All bacterial
pathogens were tested for susceptibility to fleroxacin by the Kirby-Bauer disc diffusion
method; MICs were determined by a broth microdilution method (National Committee
for Clinical Laboratory Standards, 1984).
The primary efficacy parameter was stool consistency 48 h after starting treatment.
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Secondary parameters (for exploratory analysis were time to total resolution of
diarrhoea and all other symptoms. The investigator, who was blinded throughout the
evaluation, assessed the overall clinical outcome at 72 h, denning cure as the absence of
symptoms, improvement as reduced frequency and a change of stool consistency from
liquid to soft and failure as persistently liquid stools and/or no reduction in frequency.
Safety was assessed by recording the adverse events experienced by patients in the three
groups.
Statistical analysis was performed by Chi-square or Kruskal-Wallis tests. Where
necessary, the Fisher exact test was applied to confirm the results of the Chi-square test.
A P value <0-05 was considered significant. In order to avoid controlling the Type I
error for multiple comparisons of the same parameter, orthogonal partitions of the
overall test statistics were performed as follows: (i) placebo vs fleroxacin-1 or
fleroxacin-2; (ii) fleroxacin-1 vs fleroxacin-2.
Results
A total of 195 patients, of whom 66 received placebo, 64 received fleroxacin 400 mg for
one day and 65 received fleroxacin 400 mg for two days, were entered into the study.
Forty-four patients were excluded from evaluation for the following reasons: concomi-
tant treatment (22 patients); protocol violations (nine); incorrect duration of therapy
(five); re-entry into the study resulting in exclusion of the second treatment episode from
analysis (three); premature withdrawal because of adverse events (three); failure to
return for the follow-up interview (two). One hundred and fifty-one patients were
therefore included in the analysis of efficacy; of these 151, there were 49 in the placebo
group, 54 in the fleroxacin-1 and 48 in the fleroxacin-2 groups respectively. The three
groups were similar in terms of male'.female ratio (54-59% males) and age (means
36-39 ±11-12 years).
The pre-treatment clinical signs and symptoms of travellers' diarrhoea were also
similar in the three groups (Table I); mucus diarrhoea was observed most frequently
Table I. Pre-treatment clinical signs and symptoms of patients with travellers' diarrhoea
Sign/symptom
Abdominal
cramp:
Nausea:
Vomiting:
absent
mild
moderate
severe
absent
mild
moderate
severe
absent
mild
moderate
severe
placebo group
(n = 49)
7(14)
14 (29)
20(41)
8(16)
25(51)
13(27)
10 (20)
1 (2)
38 (78)
6(12)
5(10)
No. (%) of patients
fleroxacin-1 group
(n = 54)
6(11)
10(19)
29(54)
9(17)
19 (35)
14 (26)
15 (28)
6(11)
41 (76)
2 (4)
3 (6)
8(15)
fleroxacin-2 group
(n = 48)
7(15)
11(23)
19(40)
11(23)
16 (33)
14(29)
11(23)
7(15)
41 (85)
3 (6)
2 (4)
2 (4)
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Table II.
Pathogen
Bacteria total
ETEC
Salmonella spp.
P. shigelloides
Aeromonas spp.
Protozoa total
Entamoeba histolytica (cyst)
E. coli
E. histolytica (trophozoite)
Entamoeba hartmannii
Entamoeba nana
Giardia lamblia
Iodamoeba bulschlii
No pathogen(s)
No specimen received
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Enteric pathogens isolated before treatment
placebo group
21
14 (29)
2 (4)
1 (2)
1 (2)
6
3 (6)
2 (4)
2 (4)
—
—
—
—
25 (51)
—
No. (%) of pathogens
fleroxacin-1 group
23
12 (22)
5 (9)
2 (4)
1 (2)
11
5 (9)
4 (7)
2 (4)
2 (4)
1 (4)
1 (2)
1 (2)
24(44)
2 (4)
fleroxacin-2 group
25
18 (38)
5(10)
1 (2)
—
1
—
—
—
—
—
1 (2)
23 (48)
—
amongst patients in the placebo group (27%), compared with seven and 13% in the
active treatment groups. Only two patients had blood mixed with the stools.
The distributions of pathogens isolated from the stool samples collected at entry were
similar in all three treatment groups (Table II). In approximately half of the samples no
pathogen was identified. The most common bacterial pathogens in all three groups
were ETEC strains. MICs of fleroxacin for the 61 ETEC isolates varied between O06
and l-0mg/L, for Salmonella spp. (n = 15) between 013 and 05 mg/L and for the
Plesiomonas shigelloides isolates (n = 13) between O06 and 05 mg/L; the MICs for the
three Aeromonas spp. were the same (025 mg/L). No Campylobacter or Shigella spp.
were isolated.
The effect of treatment on stool consistency is shown in Table III. At 48 h the stools
were of normal consistency in 36 of 54 (67%) patients treated with fleroxacin for one
day, in 34 of 48 (71%) patients treated with fleroxacin for two days and in 18 of 49 (37%)
Table III. Stool consistency at 12-hourly intervals for patients included in the analysis of efficacy
Interval (h)
after starting
treatment
Pre-treatment
0-12
12-24
24-36
36-48
placebo group
normal
10
14
21
18
(«=49)
soft
14
9
15
14
17
watery
35
30
20
14
14
Number of ]
fleroxacin-1
normal
16
32
35
36
patients
group
(n = 54)
soft
21
8
11
12
16
watery
33
30
11
7
2"
fleroxacin-2
normal
12
23
31
34
(n = 48
soft
15
6
14
12
13
group
watery
33
30
11
5°
1*
NB- If a patient did not pass any stools in a 12 h period, the stool consistency was taken to be normal
(formed).
" P<005, * P<0-Ol, compared with the placebo group.
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Table IV. Assessment of resolution of all symptoms at 12-hourly intervals for patients included in
the analysis of efficacy
Interval (h) after
starting treatment
0-12
12-24
24-36
36-^8
placebo group
(» = 49)
6 (12)
11 (22)
14 (29)
14 (29)
No. (%) of patients
fleroxacin-1 group
(n = 54)
4 (7)
22 (41)
21 (39)
28" (52)
fleroxacin-2 group
(n = 48)
2 (4)
7 (15)
21 (44)
24 ' (50)
Resolution of all symptoms is defined as: absence of abdominal cramps, nausea, vomiting, diarrhoea with
blood and diarrhoea with mucus; normal stool consistency, temperature < 37-5°C (if recorded).
* P<005 compared with placebo group.
patients who received the placebo; the differences in response rates between the
fleroxacin-treated groups and the placebo group were statistically significant (P<001),
but the difference between the two fleroxacin groups was not. Moreover, unformed
stools produced by most of the fleroxacin-treated patients had become soft, whereas
those produced by patients in the placebo group were watery or soft in equal numbers.
The effects of fleroxacin on stool consistency were similar when the patients were
grouped into those from whom a bacterial pathogen was isolated at entry and those
from whom a pathogen was not isolated.
The time to complete resolution of diarrhoea was shorter in the two fleroxacin-
treated groups; by 36 h, symptoms had resolved in 14% of patients in the placebo group
and in 50% of patients in both groups given fleroxacin. By 48 h, these figures had
increased to 37%, 67% and 71% for the placebo, fleroxacin-1 and fleroxacin-2 groups
respectively. The mean time to production of the last unformed stool was 270 and
27-3 h in the two fleroxacin groups and 45-1 h in the placebo group.
An assessment of the resolution of all symptoms at 12-hourly intervals is shown in
Table IV. At 48 h, 14 of 49 (29%) of placebo-treated patients experienced resolution of
all symptoms compared with 28 of 54 (52%) and 24 of 48 (50%) of patients treated with
fleroxacin for one and two days respectively. The differences between the fleroxacin and
placebo groups were statistically significant (P < 0-05), but the difference between the
two fleroxacin groups was not.
The investigators' evaluation of clinical response at 72 h is given in Table V; there
Table V. Investigator's evaluation of clinical response at 72 h
No. (%) of patients
placebo group fleroxacin-1 group fleroxacin-2 group
Response (n = 49) (n = 54) (n = 48)
Cure
Improvement
Failure
Not assessable
23 (47)
15(31)
10 (20)
1 (2)
43(80)
6(11)
4 (7)
1 (2)
39 (81)
7(15)
2 (4)
—
Table VI. Adverse events and their relationships to the trial drugs
No. of events reported and relationship to trial drugs
placebo group fleroxacin-1 group fleroxacin-2 group
Adverse events remote possible probable remote possible probable remote possible probable
Gastrointestinal (nausea, vomiting etc.) 2 7 1 4 14 8 7 15 7 3)
Nervous system (insomnia, headache etc.) 1 2 — 3 4 3 4 7 8 =
Musculo-skeletal (arthralgia, myalgia) 1 3 — 4 4 — 6 6 — ™
Skin (rash, pruritus etc.) — — 1 1 — — 1 4 1 S.
General (fatigue, pain etc.) 5 11 2 1 10 3 5 14 —
Miscellaneous — — — 2 6 — — — —
Total 9 23 4 15 38 14 23 46 16
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was a statistically significant difference in cure rates between the fleroxacin-treated
groups and the placebo group (P < 0-01). Over 80% of patients treated with fleroxacin
were considered cured, compared with 47% of patients given the placebo. There was no
significant difference in the proportions of patients who were cured, improved or not
improved according to whether a bacterial pathogen had or had not been identified. Of
the two patients who failed to respond, and from whom a pathogen was isolated, one
was infected with a strain of ETEC and the other with both an ETEC and a Salmonella
spp.
Safety was evaluated in 190 patients, of whom 64 received placebo, 61 were in the
fleroxacin-1 group and 65 were in the fleroxacin-2 group. Adverse events judged by the
investigator to be remotely, possibly or probably related to the trial drugs (Table VI)
were reported by 25 of 64 (39%) patients in the placebo group (36 incidents), 36 of 61
(59%) in the fleroxacin-1 group (67 incidents) and 42 of 65 (65%) in the fleroxacin-2
group (85 incidents); the differences between the placebo and fleroxacin groups were
statistically significant (f<0-01). The most frequently reported adverse event was
fatigue, which might have been accounted for by the gastrointestinal infection itself; this
was observed in 27%, 23% and 28% of patients in the placebo, fleroxacin-1 and
fleroxacin-2 groups respectively. Other adverse events, which included nausea, constipa-
tion, insomnia, headache and dizziness, were more common in the two fleroxacin
groups. Insomnia, skin reactions (rash, pruritus, sunburn) and arthralgia were reported
more frequently by patients who received fleroxacin for two days. Four patients
withdrew prematurely from the study because of adverse events. Two patients (one with
erythema, one with abdominal pain and constipation) were in the placebo group and
two (one with sunburn and one with insomnia, myalgia and prickly skin) were in the
fleroxacin-2 group. None of the adverse events was considered serious.
Discussion
The 400 mg dosage of fleroxacin was chosen for this study because the serum concen-
trations achieved after a single oral dose (Cnax 4-24 ± 1 -08 mg/L) (Weidekamm et al,
1988) are higher than the MIC90s (0-5 mg/L) for those pathogens usually associated
with gastrointestinal tract infection (Manek, Andrews & Wise, 1986). Ten to 15% of
fleroxacin is excreted unchanged in the faeces, and only 0-5% is in the form of the
JV-demethyl derivative; this corresponds to a daily excretion of approximately 30 mg
(7-5%) of a 400 mg dose. Assuming faeces are produced at the rate of 200 g/day,
fleroxacin concentrations would normally be 100-200 jig/g. Additionally, 2-7% of a
dose is recoverable from bile obtained via a T-tube drain during a period of 24 h. The
mean maximum biliary concentrations are ^ 10 mg/L following a single oral dose of
400 mg. Thus, the concentrations of active drug achieved in the gastrointestinal tract
substantially exceed the MICs of important bacterial enteropathogens.
Treatment was limited to one or two days because previous studies had shown
excellent results after equally short periods (Ericsson et al., 1990; Petrucelli et al., 1992)
and because self-treatment should be limited to 48 h (Farthing et al, 1992). A control
group was considered justifiable on the grounds that travellers' diarrhoea is self-
limiting; its inclusion also enabled a more reliable assessment of the safety profile of
fleroxacin.
Approximately 80% of fleroxacin-treated patients were cured after 72 h, compared
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with 47% of patients who received the placebo. These results were similar to those of a
previous study in which 74% of norfloxacin-treated patients were cured by 72 h
compared with 38% in the placebo group (Wistrom et al, 1989). Time until production
of the last unformed stool was shorter than that reported in a study of a different
patient population in which ciprofloxacin was used (Petrucelli et al, 1992).
In the present study, pathogens were not isolated from 47-7% of patients; this was
higher than previously reported rates where the faeces of 20-40% of patients with
travellers' diarrhoea failed to yield an enteric pathogen (Sack, 1990). Our low isolation
rate may be accounted for by the long interval between collection and microbiological
examination of the specimens, which may have reduced the likelihood of detecting
Campylobacter spp. in particular. Additionally, it has been suggested that previously
unrecognized, antibiotic-susceptible bacteria may play an aetiological role, the magni-
tude of the effect of antibiotics being greater than would otherwise be expected from
their activities against the known bacterial pathogens (Sack, 1990). No attempt was
made to exclude viral causes of travellers' diarrhoea in this study.
Antimicrobial susceptibility in vitro does not invariably predict a favourable clinical
response (Keusch, 1988) and persistence of the pathogen does not correlate with
prolonged diarrhoeal symptoms (Ericsson et al., 1988). For this reason, test-of-cure
stool cultures were not obtained. This was justified by the observation that the effects of
fleroxacin on stool consistency were similar, irrespective of whether or not pathogens
were isolated from pre-treatment faecal samples.
Short-term self-treatment with antibiotics for travellers' diarrhoea has distinct advan-
tages over chemoprophylaxis as both antibiotic usage and treatment time are markedly
reduced. Furthermore, it may be unacceptable to some travellers to take antibiotics for
prolonged periods.
The fluoroquinolones are highly active in vitro against a broad range of enteric
pathogens, including ETEC, Salmonella spp., Shigella spp., Yersinia enterocolitica,
Campylobacter jejuni and Vibrio spp. They are also well tolerated and have a reduced
capacity for promoting the development of resistance (Ericsson et al, 1987; Scott et al.,
1990). Norfloxacin, in a dosage of 400 mg daily, has been shown to be effective as short-
term prophylaxis for acute diarrhoea (Scott et al., 1990). Similarly, ciprofloxacin
(500 mg daily) conferred 94% protection against the onset of travellers' diarrhoea (Reves
et al., 1988). However, in another study, ciprofloxacin and co-trimoxazole were equally
effective as treatment for travellers' diarrhoea in American students visiting an area of
Mexico where trimethoprim resistance amongst bacterial enteropathogens was low
(Ericsson et al., 1987). The average durations of diarrhoea were 29, 20 and 81 h for
patients given ciprofloxacin, co-trimoxazole and placebo respectively.
Fleroxacin is a new fluoroquinolone with both a broad antibacterial spectrum which
includes the organisms commonly causing diarrhoea (Hohl et al., 1988) and superior
pharmacokinetics (Weidekamm et al., 1988). In the present study, 400 mg of fleroxacin
was administered once daily for one or two days. Approximately 50% of patients
treated with this agent were relieved of all symptoms by 48 h, compared with only 29%
of those who received a placebo. Adverse events were reported by 39%, 59% and 65% of
patients in the placebo, fleroxacin-1 and fleroxacin-2 groups respectively. None of these
was considered serious and only two patients in the fleroxacin-2 group withdraw from
the study prematurely as a result of adverse reactions. Fatigue was the most frequently
recorded adverse event, but was reported by similar numbers of patients in each of the
three groups. Other adverse events, including insomnia, skin rash, erythema, sunburn
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and arthralgia, were reported more often by patients in the fleroxacin-2 group than by
those in the fleroxacin-1 group.
Fleroxacin was well tolerated when given as a single 400 mg dose, and since the one-
and two-day regimens were comparable with respect to efficacy, a single dose of
fleroxacin would therefore be the treatment of choice for patients with travellers'
diarrhoea, expecially in those areas of the world where resistance to other antibiotics is
high. Further studies involving larger numbers of patients will be required to confirm
our findings and to evaluate the benefits of combining fleroxacin with loperamide.
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